The loss of life of a second teenage boy from liver failure brought on by a gene remedy from Sarepta Therapeutics has left the Duchenne muscular dystrophy neighborhood indignant, fearful, and divided over whether or not to keep up hope within the remedy.
Kameron Lawson discovered concerning the boy’s loss of life from a cellphone name from his son’s neurologist on Sunday morning. His personal 10-year-old son, Konner, acquired the therapy, referred to as Elevidys, in early April and started experiencing indicators of liver failure six weeks later. He has been hospitalized a number of instances with liver issues since then, and his prognosis stays unsure.
Listening to {that a} second boy with Duchenne had died from liver failure after receiving Elevidys was a shock, mentioned Kameron Lawson, talking to STAT on Sunday night time from their dwelling in Stockton, Calif. “This child died from the identical factor we’re attempting to combat off proper now,” mentioned Lawson. “It actually despatched it dwelling for us the place we’re at proper now.”
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the biotech sector — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
